Loading...
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
BACKGROUND: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and ran...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3493328/ https://ncbi.nlm.nih.gov/pubmed/22681723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-0500-5-283 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|